Immunicum shares cancer vaccine update
The company recently finished the Phase I/II study of its cancer vaccine, INTUVAX. The study involved 12 patients who have metastatic renal cell carcinoma. Out of 11 patients who received the vaccine and were able to be evaluated, seven are still alive.
The median survival rate for the entire patient population in the study now stands at more than 23 months, in contrast to the 15.2 months that patients typically live after receiving the standard cancer drug sunitinib, Karlsson-Parra said.
Patients with poor prognoses are expected to have an overall median survival of more than 22 months, as opposed to the nine months for patients typically treated with sunitinib.
Patients who received intermediate prognoses have an estimated median overall survival rate of approximately 27 months, in contrast to the 26 months for patients receiving sunitinib.
The symposium, held at the Karolinska Institutet in Sweden, provides an opportunity for researchers and scientists involved in clinical and translational immunology to learn from one another. Topics include cell transplantation, immune tolerance, cancer immunotherapy, mesenchymal stromal cell therapy, and organ and composite tissue transplantation.
Karlsson-Parra’s presentation was made in conjunction with a talk by Dr. Steven A. Rosenberg, a leading researcher in adoptive immunotherapy from the National Cancer Institute in Maryland.